An open label study to evaluate the efficacy and tolerability of erenumab in the management of persistent redness and flushing in rosacea - STOP ROS Study

Rigshospitalet Glostrup0 sites30 target enrollmentDecember 9, 2019

DrugsAimovig (Erenumab)

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Not specified
Sponsor: Rigshospitalet Glostrup
Enrollment: 30
Status: Active, not recruiting
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

December 9, 2019

End Date

TBD

Last Updated

4 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

Rigshospitalet Glostrup

Eligibility Criteria

Inclusion Criteria

•Erythematotelangiectatic rosacea with a minimum of 15 days in the run\-in period of either:
•oPSA \> 2 for a minimum 15 days, and/or
•oModerate, severe or extreme flushing for a minimum of 15 days measured by the Flushing Assessment Tool (PSA)
•Men and women aged 18 – 65 years
•Minimum 12 months of rosacea prior to trial
•If patient has concurrent migraine, a daily headache diary must be filled out
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range 30

Exclusion Criteria

•Systemic treatment for rosacea ended less than five half\-lives or 28 days ago, whichever is longest
•Topical treatment for rosacea ended less than five half\-lives or 28 days ago, whichever is longest
•Cardiovascular disease of any kind, including cerebrovascular disease
•Hypertension on the experimental day (systolic blood pressure \> 150 mmHg and/or diastolic blood pressure \> 100 mmHg)
•Hypotension on the experimental day (systolic blood pressure \< 90 mmHg and/or diastolic blood pressure \< 50 mmHg)
•Ongoing psychiatric disease of any kind – unless it has been effectively treated with a stable treatment for at least 2 months.
•Anamnestic or clinical symptoms of any kind that are deemed relevant for study participation by the physician who examines the patient
•Pregnant or breastfeeding women, or women expecting to conceive during the study
•Women of childbearing potential who are unwilling to use an acceptable method of effective contraception during treatment through 16 weeks after the last dose of erenumab. Acceptable methods of effective birth control include not having intercourse (true abstinence, when this is in line with the preferred and usual lifestyle of the subject), hormonal birth control methods (pills, shots/injections, implants, or patches), intrauterine devices, surgical contraceptive methods (vasectomy with medical assessment of the surgical success of this procedure or bilateral tubal ligation), or two barrier methods (each partner must use one barrier method) with spermicide \- males must use a condom with spermicide; females must choose either a diaphragm with spermicide, OR cervical cap with spermicide, OR contraceptive sponge with spermicide. Female subjects not of childbearing potential are defined as any female who: is post\-menopausal by history, defined as:
•Age \= 55 years with cessation of menses for 12 or more months, OR